Search people, articles, bills, and more
This bill matters because cancer remains a leading cause of death and a major health challenge for millions of Americans. By substantially increasing funding for cancer research, it aims to accelerate the discovery of new therapies, improve early detection methods, and ultimately save lives and reduce suffering. If this bill doesn't pass, the pace of cancer research might slow, potentially delaying breakthroughs that could benefit countless patients.
Furthermore, the bill addresses a critical and immediate problem: shortages of life-saving cancer drugs. These shortages can force patients to delay or interrupt treatment, often with severe consequences. By requiring a thorough study and recommendations, the bill seeks to create lasting solutions to ensure that cancer patients have consistent access to the medications vital for their survival and recovery. Without this bill, the underlying causes of these shortages might not be systematically addressed, leaving patients vulnerable to future disruptions.
No reactions yet. Be the first to weigh in.
This bill matters because cancer remains a leading cause of death and a major health challenge for millions of Americans. By substantially increasing funding for cancer research, it aims to accelerate the discovery of new therapies, improve early detection methods, and ultimately save lives and reduce suffering. If this bill doesn't pass, the pace of cancer research might slow, potentially delaying breakthroughs that could benefit countless patients.
Furthermore, the bill addresses a critical and immediate problem: shortages of life-saving cancer drugs. These shortages can force patients to delay or interrupt treatment, often with severe consequences. By requiring a thorough study and recommendations, the bill seeks to create lasting solutions to ensure that cancer patients have consistent access to the medications vital for their survival and recovery. Without this bill, the underlying causes of these shortages might not be systematically addressed, leaving patients vulnerable to future disruptions.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)
| AMOUNT | PROGRAM | TYPE | YEARS |
|---|---|---|---|
| An amount equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022 (specific dollar amount not defined in bill text) | National Cancer Institute (for cancer research) | mandatory | Fiscal years 2026 through 2030 |